On May 25, 2023, Camac Partners, LLC filed a preliminary proxy statement soliciting proxies and recommending the shareholders of Forte Biosciences, Inc. to vote for the election of its 2 nominees, Michael G. Hacke and Chris McIntyre, and not to vote for the 2 Company nominees, Lawrence Eichenfield and Paul A. Wagner, at the Company?s 2023 annual shareholders meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.601 USD | -4.60% | -19.33% | -26.86% |
13/05 | Tocagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
18/03 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.86% | 21.87M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Camac Partners Solicits Proxies from Shareholders of Forte Biosciences